The success story of indolent disease treatment expanded to difficult-to-treat patient groups
Developments in therapies for AML - chemotherapy, targeted therapy and immunotherapy
Hagop M. Kantarjian
COMy 2017: Day 2 discussion on relapsed myeloma, treatment, plasma cell leukemia and awards
Arnon Nagler et al.
BCR inhibitors improving CLL patient outcomes
BCL2 inhibition and CLL: the role of venetoclax